Metaraminol Gh Pharma (Uk)

Metaraminol, the active ingredient in Metaraminol Gh Pharma (Uk), is an alpha‑adrenergic agonist presented as an injectable solution for intravenous use. It treats hypotension, shock, and cardiac arrest in acute care settings.

GNH USA supplies Metaraminol Gh Pharma (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metaraminol acts on the peripheral alpha‑1 adrenergic receptors to raise systemic vascular resistance, making it useful in several acute cardiovascular conditions.

- Hypotension: increases blood pressure by vasoconstriction when other measures are insufficient. - Shock: supports circulatory pressure in distributive or hypovolemic shock states. - Cardiac arrest: used as a vasopressor adjunct to improve coronary perfusion pressure during resuscitation.

Metaraminol may produce a range of adverse reactions, from mild to severe, depending on dose and patient condition.

Common Side Effects: - Hypertension: excessive rise in blood pressure. - Tachycardia: rapid heart rate as a reflex response. - Headache: due to increased vascular tone. - Nausea: gastrointestinal discomfort. - Anxiety or restlessness. - Cold extremities: peripheral vasoconstriction.

Serious or Rare Side Effects: - Myocardial ischemia: reduced heart muscle oxygenation. - Severe hypertension: risk of vascular injury. - Life‑threatening arrhythmias. - Tissue necrosis at the injection site. - Pulmonary edema. - Anaphylactic or severe allergic reactions.

Metaraminol requires careful monitoring and specific safety measures in clinical practice.

- Cardiovascular monitoring: continuous blood pressure and heart‑rate observation. - Dose titration: adjust infusion rate to achieve target pressure. - Contraindication in severe hypertension: avoid rapid over‑correction. - Caution in coronary artery disease: risk of myocardial ischemia. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metaraminol can interact with several drug classes, altering its pressor effect or cardiovascular response.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may cause excessive pressor response. - Other alpha‑adrenergic agonists: risk of severe hypertension. - Indirect sympathomimetics (e.g., ephedrine): additive vasoconstriction.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt reflex tachycardia. - Calcium channel blockers: can affect vascular tone. - Diuretics: may exacerbate hypovolemia. - Anesthetic agents: potential for unpredictable hemodynamic changes. - ACE inhibitors: may influence blood pressure control.